Colonial Trust Advisors Buys 1,507 Shares of Amgen Inc. $AMGN

Colonial Trust Advisors lifted its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 85.1% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 3,278 shares of the medical research company’s stock after acquiring an additional 1,507 shares during the quarter. Colonial Trust Advisors’ holdings in Amgen were worth $925,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. TAGStone Capital Inc. lifted its holdings in Amgen by 0.8% in the 3rd quarter. TAGStone Capital Inc. now owns 4,101 shares of the medical research company’s stock worth $1,157,000 after purchasing an additional 32 shares during the last quarter. BBR Partners LLC lifted its stake in shares of Amgen by 0.5% in the third quarter. BBR Partners LLC now owns 7,117 shares of the medical research company’s stock worth $2,008,000 after buying an additional 32 shares during the last quarter. JFS Wealth Advisors LLC lifted its stake in shares of Amgen by 3.2% in the third quarter. JFS Wealth Advisors LLC now owns 1,070 shares of the medical research company’s stock worth $302,000 after buying an additional 33 shares during the last quarter. Wealth Quarterback LLC boosted its holdings in shares of Amgen by 1.6% during the 3rd quarter. Wealth Quarterback LLC now owns 2,210 shares of the medical research company’s stock worth $624,000 after buying an additional 34 shares during the period. Finally, DDFG Inc grew its stake in Amgen by 1.1% in the 3rd quarter. DDFG Inc now owns 3,014 shares of the medical research company’s stock valued at $850,000 after buying an additional 34 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Price Performance

Shares of AMGN stock opened at $384.33 on Thursday. Amgen Inc. has a 12 month low of $261.43 and a 12 month high of $387.49. The company has a market capitalization of $207.18 billion, a P/E ratio of 27.01, a P/E/G ratio of 3.79 and a beta of 0.46. The stock has a 50 day moving average of $346.58 and a two-hundred day moving average of $318.34. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. The business had revenue of $9.87 billion during the quarter, compared to analyst estimates of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.During the same period in the prior year, the company posted $5.31 earnings per share. Amgen’s revenue was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, equities analysts expect that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 13th will be given a dividend of $2.52 per share. This is an increase from Amgen’s previous quarterly dividend of $2.38. The ex-dividend date is Friday, February 13th. This represents a $10.08 annualized dividend and a dividend yield of 2.6%. Amgen’s dividend payout ratio (DPR) is presently 70.84%.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on AMGN. Truist Financial upped their price target on shares of Amgen from $318.00 to $319.00 and gave the company a “hold” rating in a report on Thursday, January 8th. Wall Street Zen cut Amgen from a “buy” rating to a “hold” rating in a research report on Saturday, February 21st. Leerink Partners raised their target price on Amgen from $305.00 to $355.00 and gave the company an “outperform” rating in a report on Wednesday, February 4th. DZ Bank lifted their price target on Amgen from $335.00 to $364.00 in a research report on Monday, November 10th. Finally, Argus increased their price objective on Amgen from $360.00 to $400.00 and gave the company a “buy” rating in a research report on Friday, February 6th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, eleven have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Amgen presently has an average rating of “Moderate Buy” and an average target price of $351.76.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.